Information profile @ a Glance
- Hydroxychloroquine, sold under the brand name Plaquenil among
others, is a medication used to prevent and treat malaria in areas where
malaria remains sensitive to chloroquine. Other uses include treatment
of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken
by mouth
- Hydroxychloroquine is in a class of drugs called antimalarials. It
is used to prevent and treat acute attacks of malaria. It is also used
to treat discoid or systemic lupus erythematosus and rheumatoid
arthritis in patients whose symptoms have not improved with other
treatments
- Only limited clinical trial data available to date to evaluate use
of hydroxychloroquine for treatment or prevention of COVID-19
- Emergency use authorization (EUA) for hydroxychloroquine: FDA issued
an EUA that permits distribution of the drug from the strategic national
stockpile (SNS) for use only in adults and adolescents weighing 50 kg or
more hospitalized with COVID-19 for whom a clinical trial is not
available or participation not feasible
- FDA states
that, based on the totality of scientific evidence available, it is
reasonable to believe that the drug may be effective in treating
COVID-19 and that, when used under the EUA conditions, known and
potential benefits outweigh known and potential risks.
- Efficacy measures: Initial studies evalu-ating hydroxychloroquine
based efficacy of the drug on negative conversion in naso-pharyngeal
samples at day 6 or 7. 7, 18 RT-PCR tests using upper and lower
respiratory specimens (including nasopharyngeal and oropharyngeal swabs)
are recommended for diagnosis of COVID-19; 19, 21 however, dynamics of
SARS-Cov-2 in infected pa-tients (untreated or treated) and presence of
the virus at various body sites over the course of infection have not
been fully determined.
|
Basics
- Treatment of COVID-19
Infection- A Systematic Literature Review
- Pharmacology of
Hydroxychloroquine
- Studies underway
- Small Trial
- Shorten time to recovery
- FAQ - COVID Management
Companies
- Global Company
- Company - India
- Exporter of Pharmaceutical Products - India
- Company - Product monograph - Ontario
- Company in the News
Product Information
- Monograph - Hydroxychloroquine Sulfate
- Product Profile
- Hydroxychloroquine sulfate properties
- Product Characteristics
Technology Information
- Planning of Hydroxychloroquine’s Syntheses
- Manufacturing process
- SARS-CoV-2 in vitro
- Clinicl Trial - Patients with Dyslipidemia
Usage for COVID-19
- Emergency use authorization
- Advisory on the use of Hydroxychloroquin
- COVID-19 Drug Therapy
- Clinical Trials
- Assessment of Evidence for
COVID-19-Related Treatments
- Binding to the SARS-CoV-2 Spike (S)Protein
- Chloroquine-Hydroxychloroquine
Applications
- Study of Hydroxychloroquine &
Treatment plan
- Endothelial
dysfunction
- Hydroxychloroquine
for treating COVID-19
- A Therapeutic Choice
in Diabetes Mellitus
- Antiphospholipid
Antibody-Induced Inhibition Of Trophoblast Migration
- Effective in
inhibiting SARS-CoV-2 infection in vitro
Market Scenario
- The product in focus
- Market Authorization
- Company - Global Supply Chain
- European Advisory
- Consultant - Market reports
Order the database Today |